M2 Pharma - Therapy Areas

AstraZeneca's Etcamah misses primary endpoint in Phase III breast cancer trial

14 September 2026 - Biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (NYSE:AZN) disclosed on Monday that its Phase III SERENA-4 trial of Etcamah (camizestrant) in combination with palboci...

GSK reports positive Jideytro data supporting potential first-line lung cancer use

14 September 2026 - Biopharmaceutical company GSK plc (LSE: GSK) (NYSE: GSK) on Monday reported positive registrational Phase I/II ARROS-1 data for Jideytro (zidesamtinib) in previously untreated ROS1...

Akeso presents positive results from registrational Phase III study of ivonescimab

14 September 2026 - Chinese biopharmaceutical company Akeso Inc (HK:9926) announced on Sunday the presentation of positive overall survival (OS) results from the randomised, double-blind, multicentre,...

ABL Diagnostics files bid to acquire IntegraGen

11 September 2026 - ABL Diagnostics (Euronext Paris:ABLD), a provider of molecular biology tests, announced on Friday that it has filed a bid to acquire the business operations and assets of IntegraGe...

Tyra Biosciences declares positive Phase 2 results for oral dabogratinib in bladder cancer

9 September 2026 - Biotechnology company Tyra Biosciences Inc (Nasdaq: TYRA) reported on Wednesday that its initial Phase 2 SURF302 results for oral dabogratinib in patients with FGFR3-altered low-gra...

Harbour BioMed partner raises USD225m to advance neoadjuvant immuno-oncology therapy porustobart

9 September 2026 - Biopharmaceutical company Harbour BioMed (HKEX: 02142) reported on Wednesday that its partner company Solstice Oncology has launched with a USD225m Series A financing led by RA Capi...